Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene Lab's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 1162.45.
BioNexus Gene Lab's Days Inventory for the
three
months ended in Mar. 2026 was 2555.
BioNexus Gene Lab's Days Payable for the
three
months ended in Mar. 2026 was 7.6.
Therefore, BioNexus Gene Lab's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 3,709.85.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
BioNexus Gene Lab Cash Conversion Cycle Related Terms
BioNexus Gene Lab Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs QGAI, VYST, GLGI: Cash Conversion Cycle Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Cash Conversion Cycle vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
BioNexus Gene Lab's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of 3,709.85 mean?
BioNexus Gene Lab (BGLC) has a Cash Conversion Cycle of 3,709.85 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on BioNexus Gene Lab and its competitors.
Is BioNexus Gene Lab's Cash Conversion Cycle too high?
BioNexus Gene Lab's current Cash Conversion Cycle is 3,709.85. The Chemicals industry median Cash Conversion Cycle is 89.33. BioNexus Gene Lab's value of 3,709.85 is 4053% above this industry median. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Cash Conversion Cycle compare to QGAI and VYST?
BioNexus Gene Lab's Cash Conversion Cycle of 3,709.85 can be compared against companies in the Chemicals industry. The industry median Cash Conversion Cycle is 89.33. BioNexus Gene Lab's value of 3,709.85 is 4053% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Chemicals company?
The median Cash Conversion Cycle among Chemicals companies is 89.33, based on 1,579 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Cash Conversion Cycle of 3,709.85 is 4053% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median Cash Conversion Cycle is 89.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Cash Conversion Cycle is 3,709.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.68 — trading 22.6% below its estimated fair value. The current Cash Conversion Cycle is 3,709.85 and 4053% above the Chemicals industry median of 89.33. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Cash Conversion Cycle is 3,709.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.68 is trading 22.6% below its estimated GF Value™ of $2.17.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
Cash Conversion Cycle: 3,709.85
GF Value™: $2.17 vs. price of $1.68 (22.6% below fair value)
Industry Position: 4053% above the Chemicals median
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
